Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut

Stock Track

Apr 23

Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.

The decline follows a series of analyst rating downgrades and a significant reduction in the company's earnings guidance. Citi downgraded Cochlear to "sell" from its previous rating, slashing its price target to A$95 per share, citing a "laundry list of headwinds far beyond what we think most anticipated" from the company's recent trading update.

UBS also cut its recommendation to neutral, warning that Cochlear has limited scope to lift annual sales growth back to 10% anytime soon, noting a drop in U.S. unit sales and pressure from overburdened European health systems and reimbursement cuts in China. The company had previously slashed its forecast for annual earnings, with Citi lowering its FY26 net profit after tax estimates by 22% and reducing its implant growth rate forecast from high to mid-single digits amid lower-than-expected demand in developed markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169620205"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169620205\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169620205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169620205","market":"hk","top_or_hot":-1,"title":"Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut","media":"Stock Track","content":"<p>Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.</p><p>The decline follows a series of analyst rating downgrades and a significant reduction in the company's earnings guidance. Citi downgraded Cochlear to \"sell\" from its previous rating, slashing its price target to A$95 per share, citing a \"laundry list of headwinds far beyond what we think most anticipated\" from the company's recent trading update.</p><p>UBS also cut its recommendation to neutral, warning that Cochlear has limited scope to lift annual sales growth back to 10% anytime soon, noting a drop in U.S. unit sales and pressure from overburdened European health systems and reimbursement cuts in China. The company had previously slashed its forecast for annual earnings, with Citi lowering its FY26 net profit after tax estimates by 22% and reducing its implant growth rate forecast from high to mid-single digits amid lower-than-expected demand in developed markets.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cochlear Plummets 5.02% Intraday Following Analyst Downgrades and Earnings Forecast Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-23 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.</p><p>The decline follows a series of analyst rating downgrades and a significant reduction in the company's earnings guidance. Citi downgraded Cochlear to \"sell\" from its previous rating, slashing its price target to A$95 per share, citing a \"laundry list of headwinds far beyond what we think most anticipated\" from the company's recent trading update.</p><p>UBS also cut its recommendation to neutral, warning that Cochlear has limited scope to lift annual sales growth back to 10% anytime soon, noting a drop in U.S. unit sales and pressure from overburdened European health systems and reimbursement cuts in China. The company had previously slashed its forecast for annual earnings, with Citi lowering its FY26 net profit after tax estimates by 22% and reducing its implant growth rate forecast from high to mid-single digits amid lower-than-expected demand in developed markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COH.AU","symbol_name":"COCHLEAR LTD","start_time":0,"source_url":"","article_id":"1169620205","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169620205","pubTimestamp":1776914566,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.The decline follows a series of analyst rating downgrades and a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COH.AU":"COCHLEAR LTD"},"translate_title":"个股追踪|分析师下调评级及下调盈利预期后科利耳盘中暴跌5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":1},"content_text":"Cochlear Ltd's stock fell 5.02% during intraday trading on Thursday, extending recent heavy losses for the hearing implant maker.The decline follows a series of analyst rating downgrades and a significant reduction in the company's earnings guidance. Citi downgraded Cochlear to \"sell\" from its previous rating, slashing its price target to A$95 per share, citing a \"laundry list of headwinds far beyond what we think most anticipated\" from the company's recent trading update.UBS also cut its recommendation to neutral, warning that Cochlear has limited scope to lift annual sales growth back to 10% anytime soon, noting a drop in U.S. unit sales and pressure from overburdened European health systems and reimbursement cuts in China. The company had previously slashed its forecast for annual earnings, with Citi lowering its FY26 net profit after tax estimates by 22% and reducing its implant growth rate forecast from high to mid-single digits amid lower-than-expected demand in developed markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}